Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX – Research Report), Amgen (AMGN – ...

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is bullish on the stock ...

LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...

LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...

GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. Hoos is leaving GSK after nine ...

Sting from a scorpion Onset of local pain and tingling after a scorpion is seen in the area The main symptoms are pain, tingling and numbness at the sting site About 85% cause only local symptoms at ...

A recent sign of growing biopharma interest in PI3Kα compounds came earlier this month, when Eli Lilly announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program STX-478 for up ...

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

This 2004 Robinson R22 combines reliability and versatility, making it ideal for training, personal adventures, or light utility work. With a recent inspection and low time since overhaul on the ...

But, as this special report snapshot shows, a host of new trials and targeted therapeutics are beginning to show serious dividends.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...